TecDAX | MorphoSys: Hoffnungsträger in der entscheidenden Runde

Die MorphoSys AG (ISIN: DE0006632003) machte bereits wiederholt deutlich, das man mit Tafasitamab einen zukünftigen Topseller in der Pipeline vermutet,der ab 2020 “auf den Markt kommt” – zuerst in den …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
634